Osteoporosis Drug Blocks Spinal Damage in Zebrafish Study
This digest was compiled by AI from multiple sources — links to the originals are below.
An existing osteoporosis drug blocked the buildup of minerals and spinal fusion in zebrafish with a genetic defect linked to human disc disease, researchers from the Universities of Edinburgh and Bristol reported Wednesday. The study, published August 6, identifies several biological processes that could become targets for future back pain treatments, even as current therapies for disc degeneration are limited to surgery.
The Zebrafish Model
Researchers bred zebrafish without a functioning copy of the collagen IX gene, which is associated with early disc problems in humans. As the fish aged, they developed spinal abnormalities resembling human intervertebral disc degeneration (IVDD), including vertebral fusion and abnormal hardening of tissue between bones. The study found that mineralization began only after a supportive scaffold layer in the developing spine deteriorated. This model allowed scientists to track the sequence of damage over time.
The Mechanism
Gene activity analysis revealed disruptions in fat metabolism and the mTOR growth pathway, along with changes in phosphate regulation and vitamin A signaling. Each of these processes has been linked to abnormal mineral accumulation. The team then tested an existing osteoporosis drug and an approach targeting fat metabolism, both of which reduced the spinal damage in the zebrafish. The drug, already approved for human use, appeared to block the chain reaction that leads to disc hardening.
Treatment Potential
The findings suggest that drugs already on the market could be repurposed for IVDD, potentially reducing the need for surgery. No medication currently halts or reverses disc degeneration, and surgery remains the only long-term option for severe cases. Researchers from the University of Edinburgh noted that the zebrafish model could be used to test other therapies before human trials. The study highlights fat metabolism and mTOR as promising targets for new drugs.
What's Next
Researchers plan to test the osteoporosis drug in mammalian models of IVDD to confirm efficacy. It remains unclear whether targeting these pathways can halt disc degeneration in human patients before irreversible damage occurs.
1 source
Osteoporosis Drug Blocks Spinal Damage in Zebrafish Study
